- Conditions
- Newly Diagnosed Glioblastoma
- Interventions
- Marizomib, Temozolomide, radiotherapy
- Drug · Radiation
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 749 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Orange, California • San Francisco, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 319
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma
- Interventions
- Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
- Drug
- Lead sponsor
- SignPath Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor, Ependymoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Primary CNS Tumor
- Interventions
- Indoximod, Temozolomide, Conformal Radiation, Cyclophosphamide, Etoposide
- Drug · Radiation
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Orlando, Florida • Atlanta, Georgia + 2 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- R-(-)-gossypol acetic acid, temozolomide, gene expression analysis, mutation analysis, protein expression analysis, laboratory biomarker analysis, pharmacological study, adjuvant therapy, radiation therapy
- Drug · Genetic · Other + 2 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
- Conditions
- Glioblastoma
- Interventions
- PTK787/ZK 222584, Temozolomide, Radiation Therapy
- Drug · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Glioblastoma Multiforme
- Interventions
- Temozolomide, radiation therapy, Ascorbic Acid
- Drug · Radiation
- Lead sponsor
- Bryan Allen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Malignant Neoplasms of Brain
- Interventions
- PEP-3-KLH conjugate vaccine, daclizumab, temozolomide, placebo, PEP-3-KLH
- Biological · Drug · Other
- Lead sponsor
- John Sampson
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma Multiforme
- Interventions
- Temozolomide, Subventricular Zone radiation, Neural Progenitor Cell Sparing radiation
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
- Conditions
- Glioblastoma
- Interventions
- CC-90010, Temozolomide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glioblastoma
- Interventions
- Cannabis, Temozolomide, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Glioblastoma
- Interventions
- GammaTile®, External Beam Radiation Therapy, Temozolomide
- Device · Radiation · Drug
- Lead sponsor
- GT Medical Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 766 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Orlando, Florida • Atlanta, Georgia + 9 more
- Conditions
- Patients With Newly Diagnosed Glioblastoma
- Interventions
- PLX3397, Radiation Therapy, Temozolomide
- Drug · Radiation
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Detroit, Michigan + 4 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- dasatinib, temozolomide, placebo, radiation therapy
- Drug · Other · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 207
- States / cities
- Hartford, Connecticut • Jacksonville, Florida • Columbus, Georgia + 135 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- arsenic trioxide, temozolomide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2021
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Naperville, Illinois
- Conditions
- Glioblastoma Multiforme
- Interventions
- CT-322, Temozolomide, Radiation Therapy
- Drug · Procedure
- Lead sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Chicago, Illinois • Lexington, Kentucky + 3 more
- Conditions
- Glioblastoma
- Interventions
- Enzastaurin Hydrochloride, Placebo, Temozolomide, Radiotherapy
- Drug · Other · Radiation
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Nivolumab, Temozolomide
- Drug
- Lead sponsor
- University of Sydney
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma Multiforme
- Interventions
- Lucanthone, Temozolomide (TMZ), Radiation, Placebo
- Drug · Radiation
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- La Jolla, California • Orange, California • Amherst, New York + 2 more
- Conditions
- Malignant Glioma, Grade 4 Malignant Glioma, Glioblastoma, Gliosarcoma
- Interventions
- Radiation Therapy, Temozolomide, Bevacizumab
- Radiation · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Glioblastoma
- Interventions
- Temozolomide, Bavituximab, Radiation
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Indoximod, Partial Radiation, Full-dose Radiation, Temozolomide, Cyclophosphamide, Etoposide, Lomustine
- Drug · Radiation
- Lead sponsor
- Theodore S. Johnson
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 5
- States / cities
- Augusta, Georgia • Druid Hills, Georgia • Boston, Massachusetts + 2 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- PPX (CT2103), Temozolomide
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 9
- States / cities
- La Jolla, California • Scarborough, Maine • Worcester, Massachusetts + 6 more
- Conditions
- Adult Brain Glioblastoma
- Interventions
- Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Neuroblastoma
- Interventions
- Hu3F8 With GM-CSF
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York